Conflicts of Interest in the Development of New Interventional Medical Devices

Journal of Vascular and Interventional Radiology

Volumn 20, Issue 3, 2009, Pages 309-313

  Baerlocher, Mark Otto ^a   Millward, Steven F ^b   Cardella, John F ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; DEVICE; EDITORIAL; INTERVENTIONAL RADIOLOGY; MEDICAL ETHICS; MONEY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

RADIOGRAPHY, INTERVENTIONAL; RADIOLOGY, INTERVENTIONAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TECHNOLOGY, RADIOLOGIC; UNITED STATES;

EID: 60649097914     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2008.11.013     Document Type: Editorial

References (44)

1. Angell M. The truth about the drug companies: how they deceive us and what to do about it (2004), Random House, New York
2. Kassirer J.P. On the take: how America's complicity with big business can endanger your health (2004), Oxford University Press, New York
3. Orlowski J.P., and Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest 102 (1992) 270-273
4. Lurie N., Rich E.C., Simpson D.E., et al. Pharmaceutical representatives in academic medical centers. J Gen Intern Med 5 (1990) 240-243
5. Chren M.M., and Landefeld C.S. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271 (1994) 684-689
6. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?. JAMA 283 (2000) 373-380
7. Stelfox H.T., Chua G., O'Rourke K., and Detsky A.S. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338 (1998) 101-106
8. Choudhry N.K., Stelfox H.T., and Detsky A.S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287 (2002) 612-617
9. Weintraub A., and Barrett A. Medicine in conflict. BusinessWeek October 23 (2006). http://www.businessweek.com/magazine/content/06_43/b4006081.htm Accessed January 1, 2008
10. Yadav J.S., Wholey M.H., Kuntz R.E., et al. Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 (2004) 1493-1501
11. Wood S. Cleveland Clinic fires Dr. Jay Yadav for undisclosed conflicts of interest. Aug 18 (2006). http://www.theheart.org/article/733003.do Accessed December 23, 2008
12. Wood S. Dr. Jay Yadav sues Cleveland Clinic. December 6 (2007). http://www.theheart.org/article/832231.do Accessed December 23, 2008
13. Mantone J. Cleveland Clinic struggles with conflict resolution. The Wall Street Journal, December 7, 2007. http://blogs.wsj.com/health/2007/12/07/cleveland-clinic-struggles-with-conflict-resolution/ Accessed January 1, 2008
14. Uzdienski L. Zimmer, Depuy, Biomet, Smith & Nephew and Stryker settle DOJ investigation for $311 million. HealthPoint Capital, September 27, 2007. http://www.healthpointcapital.com/research/2007/09/27/zimmer_depuy_biomet_smith_nephew_and_stryker_settle_doj_investigation_for_311_million/ Accessed January 6, 2007
15. Uzdienski L. Star-Ledger: DOJ settlement could come this Summer. HealthPoint Capital, May 24, 2007. http://www.healthpointcapital.com/research/2007/05/24/starledger_doj_settlement_could_come_this_summer/ Accessed May 6, 2008
16. Goldstein J. Why a device maker paid docs $85 million. The Wall Street Journal, November 27, 2007. http://blogs.wsj.com/health/2007/11/27/why-a-device-maker-paid-docs-85-million/?mod=yahoo_hs Accessed January 6, 2007
17. Brown S.D., Daly J.C., Kalish L.A., and McDaniel S.A. Financial disclosures of scientific papers presented at the 2003 RSNA Annual meeting: association with reporting of non-Food and Drug Administration-approved uses of industry products. Radiology 239 (2006) 849-855
18. National Institutes of Health. Abut NIH. http://www.nih.gov/about/NIHoverview.html Accessed December 26, 2007
19. Steinbrook R. Financial conflicts of interest and the NIH. N Engl J Med 350 (2004) 327-330
20. Willman D. Stealth merger: drug companies and government research. Los Angeles Times, December 7 (2003) A1
21. Steinbrook R. Conflicts of interest at the NIH - resolving the problem. N Engl J Med 351 (2004) 955-957
22. Former Director, Elias A. Zerhouni, M.D. Biographical Sketch. http://www.nih.gov/about/director/zerhouni_archive.htm Accessed December 23, 2008
23. Nature Editorial Staff. Taking a hard line on conflicts. Nature 433 (2005) 557
24. Wadman M. NIH workers see red over revised rules for conflicts of interest. Nature 434 (2005) 3-4
25. Ready T. Strict NIH ethics rules provoke mixed response from scientists. Nat Med 11 (2005) 238
26. Kaiser J. Conflict-of-interest policy: NIH rules make some pack, others plead. Science 307 (2005) 1703
27. Stossel T. Regulating academic-industrial research relationships - solving problems or stifling progress?. N Engl J Med 353 (2005) 1060-1065
28. Hofschneider P., and Murray K. Combining science and business: from recombinant DNA to vaccines against hepatitis B virus. In: Buckel P. (Ed). Recombinant protein drugs (2001), Birkhäuser Verlag, Basel, Switzerland 43-64
29. Rennie D. Thyroid storm. JAMA 277 (1997) 1238-1243
30. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 342 (2000) 1539-1544
31. Mathews A.W., and Burton T.M. After Medtronic lobbying push, the FDA had change of heart. The Wall Street Journal, July 9 (2004) A-1
32. Taylor M. Feds investigating device makers: experts predict Medtronic settlement is first of many. Mod Healthc 36 (2006) 17
33. Rhea S. Extended warranties. While the $311 million orthopedic kickback settlement is being hailed as progress, some feel the practice will continue. Mod Healthc 37 (2007) 6-7
34. Angell M. Is academic medicine for sale?. N Engl J Med 342 (2000) 1516-1518
35. DeAngelis C. Conflicts of interest and the public trust. JAMA 284 (2000) 2237-2238
36. Department of Health and Human Services. Office of Research Integrity home page. http://ori.dhhs.gov Accessed December 26, 2007
37. Horstmann E., McCabe M.S., Grochow L., et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352 (2005) 895-904
38. Khan M.H., Lee J.Y., Rihn J.A., et al. The surgeon as a consultant for medical device manufacturers: what do our patients think?. Spine 32 (2007) 2616-2618
39. Conflicts of interests and investments. [editorial]. Can Med Assoc J 171 (2004) 1313
40. Arshinoff S. Excluding the experts?. [letter]. Can Med Assoc J 173 (2005) 849
41. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. www.icmje.org/index.html Accessed December 26, 2007
42. Detsky A.S. Sources of bias for authors of clinical practice guidelines. Can Med Assoc J 175 (2006) 1033
43. LaViolette P.A. Medical devices and conflict of interest: unique issues and an industry code to address them. Cleve Clin J Med 74 suppl (2007) S26-S28
44. Campbell E.G. Doctors and drug companies - scrutinizing influential relationships. N Engl J Med 357 (2007) 1796-1797